Cargando…
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
Inherited predisposition occurs in 5–10% of all prostate cancer (CaP) patients, but the genes involved in conferring genetic susceptibility remain largely unknown. Several lines of evidence indicate that germline mutations in BRCA1 and BRCA2 might be associated with an increased risk for CaP. Three...
Autores principales: | Vazina, A, Baniel, J, Yaacobi, Y, Shtriker, A, Engelstein, D, Leibovitz, I, Zehavi, M, Sidi, A A, Ramon, Y, Tischler, T, Livne, P M, Friedman, E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374645/ https://www.ncbi.nlm.nih.gov/pubmed/10945492 http://dx.doi.org/10.1054/bjoc.2000.1249 |
Ejemplares similares
-
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel
por: Figer, A, et al.
Publicado: (2001) -
Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients
por: Díez, O, et al.
Publicado: (1999) -
Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry
por: Tennen, Ruth I., et al.
Publicado: (2020) -
BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina
por: Solano, Angela R., et al.
Publicado: (2018) -
Identification of a founder BRCA2 mutation in Sardinia
por: Pisano, M, et al.
Publicado: (2000)